THUMPD1 Antibody

What is THUMPD1 and what is its biological function?

THUMPD1 (THUMP domain-containing protein 1) is a specific RNA adaptor protein that assists in the acetylation of mRNA and production of N4-acetylcytidine (ac4C). It functions primarily as a tRNA-binding adapter that mediates NAT10-dependent tRNA acetylation, specifically modifying cytidine to N4-acetylcytidine . The protein contains a THUMP domain, which is involved in RNA binding and modification activities. THUMPD1 is widely expressed across various tissues, with notably higher expression in bone marrow, tissues with active differentiation, and hematopoietic and lymphoid tissues . The protein has a reported length of 353 amino acid residues and a molecular mass of approximately 39.3 kDa in humans .

Recent research indicates that THUMPD1 may play significant roles in cancer progression, immune regulation, and cellular signaling pathways, making it an important target for cancer research .

What are the primary applications of THUMPD1 antibodies in research?

THUMPD1 antibodies are primarily used in the following research applications:

• Western Blot (WB): The most common application for detecting and quantifying THUMPD1 protein expression in cell and tissue lysates .

• Immunoprecipitation (IP): For isolating THUMPD1 protein complexes to study protein-protein interactions .

• Immunohistochemistry (IHC): For visualizing THUMPD1 expression patterns in tissue sections, particularly useful in cancer studies comparing expression in tumor versus normal tissues .

• Immunocytochemistry (ICC) and Immunofluorescence (IF): For determining subcellular localization of THUMPD1, which has been shown to have different functional implications when located in the cytosol versus nucleus .

These techniques have been instrumental in elucidating THUMPD1's role in various cellular processes and disease states, particularly in cancer research where expression patterns correlate with clinical outcomes .

What is the expression pattern of THUMPD1 across normal and cancer tissues?

THUMPD1 shows variable expression across different tissues, with significant differences between normal and cancer tissues:

Normal Tissues:

• Comparably expressed across most normal tissues with some exceptions

• Higher expression in bone marrow, which aligns with its active differentiation role

• Elevated expression in hematopoietic and lymphoid tissues

• Moderate expression in ovary, prostate, and uterus

Cancer Tissues:

• Significantly altered expression in 23 out of 27 cancer types compared to corresponding normal tissues

• Higher expression in most cancer types, including adrenocortical carcinoma (ACC) and liver hepatocellular carcinoma (LIHC)

• Lower expression in bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), and uterine corpus endometrial carcinoma (UCEC)

• In breast cancer specifically, THUMPD1 expression is significantly higher in cancer tissues (60.9%) compared to normal breast tissues (28.3%, p < 0.001)

These expression patterns have been validated at both mRNA and protein levels through various techniques including Western blotting and immunofluorescence .

What species reactivity can be expected with commonly available THUMPD1 antibodies?

Based on the search results, commercially available THUMPD1 antibodies demonstrate reactivity with several species:

• Human (Hu): Most extensively validated reactivity across manufacturers

• Rat (Rt): Confirmed reactivity with some antibody products

• Bovine (Bv): Some antibodies show cross-reactivity

• Guinea Pig (GP): Limited reactivity reported with select antibodies

Additionally, THUMPD1 gene orthologs have been reported in mouse, frog, zebrafish, chimpanzee, and chicken species, suggesting potential cross-reactivity with antibodies designed against conserved epitopes . When selecting an antibody for research with non-human models, researchers should verify the specific cross-reactivity of their selected antibody product, as this varies between manufacturers and individual antibody clones.

How does THUMPD1 expression correlate with cancer prognosis across different tumor types?

THUMPD1 expression demonstrates variable prognostic significance across cancer types, with both favorable and unfavorable correlations depending on the specific cancer:

Favorable prognosis (higher THUMPD1 expression associated with better outcomes):

Unfavorable prognosis (higher THUMPD1 expression associated with worse outcomes):

• Liver hepatocellular carcinoma (LIHC): Highest risk effect observed

• Cervical and endocervical cancers (CESC): Earlier recurrence with high expression

• Pancreatic adenocarcinoma (PAAD): Earlier metastasis after tumor resection with high expression

Breast cancer-specific findings:

These findings indicate that THUMPD1's role in cancer progression is complex and context-dependent, potentially related to its interaction with different signaling pathways in various tissue types .

What is the relationship between THUMPD1 expression and immune cell infiltration in tumors?

THUMPD1 expression shows significant correlations with immune cell infiltration across several cancer types, suggesting its potential role in tumor immunology:

Top cancer types with highest immune infiltration correlation:

• Colon adenocarcinoma (COAD)

• Kidney renal clear cell carcinoma (KIRC)

• Liver hepatocellular carcinoma (LIHC)

Immune cell types with significant correlation:

• Macrophages showed the strongest correlation with THUMPD1 expression

• Other significant correlations were observed with:

  • B cells

  • CD4+ T cells

  • CD8+ T cells

  • Dendritic cells

  • Neutrophils

The positive correlation between THUMPD1 expression and increased immune infiltration suggests that THUMPD1 might play a vital role in modulating the tumor immune microenvironment. Linear regression models indicated that high THUMPD1 expression may be associated with increased immune infiltration levels, potentially influencing response to immunotherapy .

How does THUMPD1 relate to immunotherapy response markers like TMB, MSI, and neoantigens?

THUMPD1 expression has been found to correlate significantly with established biomarkers of cancer immunotherapy response:

Tumor Mutational Burden (TMB):

• Significant correlation between THUMPD1 expression and TMB across multiple cancer types

• TMB is associated with resistance to anti-tumor immunotherapy and worse prognosis

Microsatellite Instability (MSI):

• THUMPD1 expression is significantly associated with MSI

• MSI is a recognized prognostic biomarker of cancer immunotherapy

Neoantigens:

• Correlation between THUMPD1 expression and neoantigen presence

• Neoantigens are important predictors of response to immune checkpoint inhibitors

Immune Checkpoint (ICP) Genes:

• THUMPD1 expression correlates with multiple immune checkpoint genes

• This suggests potential relevance for predicting response to checkpoint inhibitor therapy

These findings indicate that THUMPD1 may serve as a novel predictor to evaluate immune therapy efficacy across diverse cancer types, with potential applications in patient stratification for immunotherapy trials .

What cellular signaling pathways does THUMPD1 interact with in cancer progression?

Research has identified several key signaling pathways through which THUMPD1 mediates its effects on cancer cell behavior:

AKT-GSK3β-Snail Pathway:

• THUMPD1 overexpression activates AKT (protein kinase B)

• Activated AKT leads to phosphorylation and inhibition of GSK3β

• Inhibited GSK3β results in stabilization of Snail protein

• Stabilized Snail represses E-cadherin expression

• Reduced E-cadherin promotes epithelial-to-mesenchymal transition (EMT), enhancing invasion and migration

• AKT inhibitor (LY294002) treatment reduces the effects of THUMPD1 overexpression

YAP/Hippo Pathway Interaction:

• THUMPD1 interacts and co-localizes with YAP (Yes-associated protein)

• Despite this interaction, THUMPD1 does not significantly affect Hippo pathway activity

The interaction of THUMPD1 with these pathways helps explain its role in promoting cancer cell invasion and migration, particularly in breast cancer where cytosolic localization correlates with adverse clinical outcomes .

What are the optimal conditions for using THUMPD1 antibodies in Western blot?

For optimal results when using THUMPD1 antibodies in Western blot applications:

Protein Extraction and Loading:

• Target a loading amount of 20-30 μg of total protein per lane

• THUMPD1 has a molecular weight of approximately 39.3 kDa, so use appropriate percentage gels (10-12% SDS-PAGE)

Blocking Conditions:

• Use 5% non-fat dry milk or BSA in TBST for blocking

• Block for 1-2 hours at room temperature or overnight at 4°C

Antibody Concentrations:

• Primary antibody dilutions typically range from 1:500 to 1:2000 depending on the specific antibody

• Secondary antibody dilutions typically range from 1:2000 to 1:10000

Controls:

• Include positive control lysates from tissues known to express THUMPD1 (bone marrow, lymphoid tissues)

• Negative controls should include tissues with minimal THUMPD1 expression

• Consider using THUMPD1 knockdown or knockout cells as specificity controls

Visualization:

• Both chemiluminescence and fluorescence-based detection methods are suitable

• For quantitative analysis, use fluorescence-based detection for more accurate quantification

How can researchers distinguish between cytosolic and nuclear THUMPD1 in experimental designs?

Distinguishing between cytosolic and nuclear THUMPD1 is critical since research has shown differential prognostic significance between these localizations, particularly in breast cancer :

Subcellular Fractionation:

• Use commercial nuclear/cytoplasmic extraction kits

• Verify fractionation purity using known nuclear (e.g., Lamin B) and cytoplasmic (e.g., GAPDH) markers

• Analyze THUMPD1 expression in each fraction by Western blot

Immunofluorescence/Immunocytochemistry:

• Use THUMPD1 antibodies in conjunction with nuclear stains (DAPI or Hoechst)

• Analyze colocalization using confocal microscopy

• Quantify nuclear vs. cytoplasmic signal intensity using appropriate imaging software

• Immunofluorescence has confirmed THUMPD1 distribution throughout whole cells, with notable abundance in cytoplasm

Quantification Methods:

• For tissue samples: Use H-score or other semiquantitative scoring systems to separately evaluate nuclear and cytoplasmic staining

• For cell lines: Use fluorescence intensity ratios (nuclear:cytoplasmic) for quantitative assessment

This differentiation is particularly important in breast cancer research, where studies have shown that cytosolic, but not nuclear, THUMPD1 expression correlates with advanced TNM stage, lymph node metastasis, and poor patient prognosis .

What experimental approaches can validate THUMPD1's functional role in cancer progression?

To validate THUMPD1's functional role in cancer progression, researchers can employ several complementary approaches:

Gene Expression Modulation:

• Overexpression: Transfect cells with THUMPD1 expression vectors to assess phenotypic effects

• Knockdown/Knockout: Use siRNA, shRNA, or CRISPR-Cas9 to reduce THUMPD1 expression

• Rescue experiments: Re-introduce THUMPD1 in knockout models to confirm specificity of observed effects

Functional Assays:

• Migration assays (wound healing, transwell) to assess cell motility

• Invasion assays using Matrigel-coated transwells

• Proliferation assays (MTT, BrdU incorporation)

• Colony formation assays

• In vivo xenograft models to assess tumor growth and metastasis

Pathway Analysis:

• Western blot for downstream effectors (AKT, phospho-AKT, GSK3β, phospho-GSK3β, Snail, E-cadherin)

• Pathway inhibitors (e.g., LY294002 for AKT) to confirm signaling mechanisms

• Co-immunoprecipitation to identify protein-protein interactions (e.g., THUMPD1-YAP interaction)

Clinical Correlation:

• Compare THUMPD1 expression with clinicopathological parameters in patient cohorts

• Perform survival analyses based on THUMPD1 expression levels and subcellular localization

• Correlate with immune infiltration markers and immunotherapy response data

Research has validated THUMPD1's functional role in breast cancer using many of these approaches, demonstrating that it promotes invasion and migration via the AKT-GSK3β-Snail pathway .

How can researchers assess the relationship between THUMPD1 and immunotherapy response?

Based on the significant correlations between THUMPD1 and immune parameters, the following approaches can be used to investigate its relationship with immunotherapy response:

Bioinformatic Analysis:

• Analyze THUMPD1 expression in immunotherapy response datasets (e.g., IMvigor210)

• Use 'surv-cutpoint' function of 'survminer' R package to divide patients into high and low THUMPD1 expression cohorts

• Apply Kaplan–Meier method and log-ranked test to determine survival differences

• Investigate differences in immunotherapeutic effect using Chi-square test

Immune Parameter Correlation:

• Analyze relationships between THUMPD1 expression and:

  • Tumor mutational burden (TMB)

  • Microsatellite instability (MSI)

  • Neoantigen load

  • Immune checkpoint gene expression

  • Immune cell infiltration

Experimental Validation:

• In vitro co-culture systems with cancer cells and immune cells

• Assess immune checkpoint inhibitor efficacy in THUMPD1-high vs. THUMPD1-low cancer models

• Evaluate changes in tumor immune microenvironment after THUMPD1 modulation

Clinical Samples Analysis:

• Retrospective analysis of THUMPD1 expression in responders vs. non-responders to immunotherapy

• Prospective collection of samples from immunotherapy trials with THUMPD1 assessment

• Correlation with clinical outcomes and biomarkers of response

This multifaceted approach can help establish whether THUMPD1 is a reliable biomarker for predicting immunotherapy response across cancer types.

What are the best statistical methods for analyzing THUMPD1 expression data in clinical studies?

For robust analysis of THUMPD1 expression in clinical studies, researchers should consider the following statistical approaches:

Expression Comparison:

• t-test for comparing THUMPD1 expression between normal and cancer tissues

• ANOVA for comparing expression across multiple cancer subtypes

• Non-parametric alternatives (Mann-Whitney, Kruskal-Wallis) for non-normally distributed data

Correlation Analysis:

• Spearman correlation test for assessing relationships between THUMPD1 expression and:

  • Immune cell infiltration scores

  • TME biomarkers (TMB, MSI, neoantigens)

  • Immune checkpoint gene expression

  • Significant threshold typically set at p-value < 0.05

Multivariate Analysis:

• Multivariate Cox regression to adjust for confounding variables (age, sex, stage, grade)

• Logistic regression for binary outcomes (e.g., response to immunotherapy)

These statistical methods have been successfully applied in pan-cancer analyses of THUMPD1, revealing its variable prognostic significance across cancer types and its correlation with immune parameters .

What databases and bioinformatic tools are most useful for THUMPD1 research?

Based on the search results, several key databases and bioinformatic tools have proven valuable for THUMPD1 research:

Expression Databases:

• Genotype-Tissue Expression (GTEx): For normal tissue expression profiles

• Cancer Cell Line Encyclopedia (CCLE): For cancer cell line expression data

• The Cancer Genome Atlas (TCGA): For cancer tissue expression data and clinical correlations

Immune Analysis Tools:

• TIMER (Tumor Immune Estimation Resource): For analyzing immune cell infiltration

• IMvigor210 package: For immunotherapy response analysis

R Packages for Data Analysis:

• 'forestplot': For conducting and visualizing univariate Cox regression analysis

• 'survminer': For survival analysis and determining optimal expression cutpoints

• 'surv-cutpoint': Function for dividing patients into high and low expression cohorts

• 'ggpubr': For creating publication-quality graphs

Pathway Analysis Tools:

• Gene Set Enrichment Analysis (GSEA): For investigating potential tumorigenic mechanisms

• STRING database: For protein-protein interaction network analysis

These resources have been instrumental in comprehensive pan-cancer analyses of THUMPD1, enabling researchers to investigate its expression patterns, prognostic significance, and relationships with immune parameters across multiple cancer types .

What are the most promising applications of THUMPD1 antibodies in cancer research?

Based on current research findings, THUMPD1 antibodies show particular promise in the following research areas:

Cancer Prognosis Biomarker Development:

• THUMPD1 expression correlates with prognosis in multiple cancer types, with both favorable and unfavorable associations depending on cancer type

• Antibodies can be used to develop immunohistochemical assays for clinical prognostication

Immunotherapy Response Prediction:

• Strong correlations between THUMPD1 and immune parameters (TMB, MSI, immune cell infiltration)

• Potential to develop THUMPD1-based predictive assays for immunotherapy response

Therapeutic Target Identification:

• THUMPD1's role in promoting cancer cell invasion and migration via the AKT-GSK3β-Snail pathway

• Antibodies can help validate THUMPD1 as a potential therapeutic target

RNA Modification Research:

• THUMPD1's function in RNA acetylation and N4-acetylcytidine (ac4C) production

• Antibodies enable investigation of this emerging area of epitranscriptomics in cancer

Tumor Microenvironment Studies:

• Significant association with immune cell infiltration

• Antibodies facilitate research into THUMPD1's role in shaping the tumor immune microenvironment

These applications position THUMPD1 antibodies as valuable tools in advancing our understanding of cancer biology and developing new diagnostic and therapeutic approaches.

What are the current gaps in THUMPD1 research that need to be addressed?

Despite the growing body of research on THUMPD1, several important knowledge gaps remain:

Mechanistic Understanding:

• Precise molecular mechanisms by which THUMPD1 influences cancer progression

• Detailed characterization of THUMPD1's role in RNA modification and its downstream effects

• Complete mapping of THUMPD1's interaction partners beyond NAT10 and YAP

Cancer Type Specificity:

• Explanation for why THUMPD1 has opposite prognostic effects in different cancer types

• Cancer-specific signaling networks involving THUMPD1

Therapeutic Potential:

• Feasibility of targeting THUMPD1 for cancer therapy

• Potential synergies between THUMPD1 inhibition and existing therapies

• Development of specific THUMPD1 inhibitors

Predictive Biomarker Validation:

• Prospective validation of THUMPD1 as a biomarker for immunotherapy response

• Standardization of THUMPD1 assessment methods for clinical use

Subcellular Localization Effects:

• Further characterization of the differential roles of cytosolic versus nuclear THUMPD1

• Mechanisms controlling THUMPD1 subcellular distribution